When Time Becomes the Enemy: Rethinking Drug Resistant Tuberculosis

For physicians working in tropical medicine and infectious diseases, tuberculosis (TB) is not abstract global statistic. It is a daily clinical reality that underscores a central challenge: timely, accurate diagnosis plays an important role in patient management and transmission control efforts. TB patients arrive in consulting rooms breathless, fatigued, and too often, too late. Despite being preventable and treatable, tuberculosis remains the leading cause of death from a single infectious agent worldwide, with more than 10 million people affected and over one million deaths each year.¹

“Tuberculosis is an old disease, but it continues to kill,” says Dr. Francisco Beraldi, infectious disease physician and Ph.D. in Tropical Medicine and Infectious Diseases, at the Division of Chronic Diseases and Sexually Transmitted Infections (DCIST) of the Paraná State Department of Health (SESA-PR). “And that forces us to ask a difficult question: if this disease is treatable and potentially curable, where are we still failing?”

Drug resistance is rarely an accident

Drug‑resistant TB can emerge due to delayed diagnosis, inadequate treatment, or poor adherence. Once resistance develops, outcomes worsen, transmission continues, and therapeutic options narrow.²

“Resistance is not just a microbiological phenomenon,” Dr. Beraldi explains. “It is the predictable result of missed opportunities along the care pathway.”

The biology of Mycobacterium tuberculosis helps explain why. In cavitary lung disease, bacterial populations can reach billions of organisms, creating ideal conditions for spontaneous mutations conferring resistance. These fast‑multiplying bacilli are linked to symptoms, transmission, and the selection of naturally resistant mutants when treatment is not fully effective.³

“If you wait until cavitation appears, you are already chasing the problem,” he notes. “At that point, the patient has lung damage, is transmitting disease, and resistance may already be present.”

The high cost of waiting

Traditional diagnostic approaches have long relied on smear microscopy and culture. While culture remains an important reference method, its timelines are incompatible with the urgency of TB care. Results can take weeks, sometimes months, a time during which patients may receive ineffective therapy or none at all.⁴

“The delay is the worst part,” Dr. Beraldi says. “Some people finish months of treatment, only to learn the diagnosis or resistance profile was wrong. For the patient, that means starting from zero.”

Clinical evidence suggests: delayed or incorrect diagnosis significantly increases mortality, particularly among patients with HIV co‑infection.⁵

 Treating empirically, without confirming the etiological diagnosis, can be just as dangerous.

“Starting treatment without knowing what you’re treating can be worse than not treating at all,” he cautions. “Tuberculosis mimics many other diseases. If you stop investigating too early, you risk missing the real cause.”

Rapid molecular diagnostics change the equation

The introduction of rapid molecular diagnostics marked a turning point in TB care. Tests such as Xpert® MTB/RIF Ultra allow clinicians to detect Mycobacterium tuberculosis and rifampicin resistance within hours, with far greater sensitivity than smear microscopy.⁶

“For the first time, diagnosis and resistance detection can happen during the same clinical encounter,” says Dr. Beraldi. “That fundamentally changes how quickly we can act.”

The World Health Organization (WHO) now recommends automated, low‑complexity molecular tests as the initial approach for TB diagnosis and resistance detection. Earlier identification of resistance enables earlier treatment adjustment, reducing transmission and improving outcomes.⁷

“When you know the resistance profile from the start, you can treat correctly from day one,” he adds. “That is how you prevent drug‑resistant TB.”

Diagnostics and treatment must evolve together

Advances in diagnostics match advances in treatment. Shorter, all‑oral regimens like BPaL and BPaLM have reset expectations for patients with drug‑resistant TB, have demonstrated cure rates near 90 percent in clinical trials.^8.9

However, these regimens depend on precision. Susceptibility to key drug classes, particularly fluoroquinolones, directly determines whether a regimen is appropriate.

“You cannot choose the right regimen if you don’t know what will work,” Dr. Beraldi emphasizes. “Modern treatments require modern diagnostics.”

Beyond technology: system responsibility

While diagnostic tools are essential, they are only effective when embedded in a system that prioritizes access, speed, and clinical judgment. Delays between testing, results, and treatment initiation can erase the benefits of even the most advanced assays.⁵

“Time is not neutral in tuberculosis,” Dr. Beraldi says. “Every week of delay increases the risk of death. If we can diagnose faster, we save lives. It’s that simple.”

For clinicians, the goal is clear: no patient should fail treatment because resistance was detected too late or spend months on ineffective therapy when answers could be available within hours.

“The tools exist,” he concludes. “The challenge now is making early, accurate diagnosis the standard of care, not the exception.”

Watch the webinar recording here:

Spanish recording: https://www.cepheid.com/fr-CA/insights/webinars.html?D2C=5204078isSocialSharing%3DY&partnerref=emai…

Portuguese recording: https://www.cepheid.com/fr-CA/insights/webinars.html?D2C=5204106isSocialSharing%3DY&partnerref=emai…